The female superiority in survival in clinical stage II cutaneous malignant melanoma.
Five-year survival rates were similar in men and women with nodal metastases from malignant melanoma (clinical Stage II). This is in contrast to our previous studies on patients with localized disease (clinical Stage I) which indicated a marked female superiority in survival. To seek explanation for this, we examined in these patients with regional lymph node metastases, four factors which we previously showed to be of prognostic importance in patients with localized disease: (1) Age of patient: overall survival rate in Stage II women was markedly reduced due to extremely poor prognosis for postmenopausal women; (2) Site of primary lesion: Stage II women had a preponderance of extremity lesions, but these were not more prognostically favorable anatomic locations than axial locations; (3) Tumor thickness: women with metastatic malignant melanoma had a significantly higher proportion of very thick lesions than men; and (4) Evidence of tumor regression: although men with very thin regressing tumors had a poor prognosis, there were too few lesions of this thickness in patients with Stage II melanoma to markedly influence overall survival. It was concluded that although overall five-year survival rates in men and women with clinical Stage II malignant melanoma were similar, if these patients were matched by age and thickness of primary lesion, a female superiority in survival did exist for young patients with very thick tumors.